Anadis to sell Travelan in USA
Wednesday, 12 October, 2005
Melbourne biopharmaceutical company Anadis (ASX:ANX) has received legal advice that its over-the-counter traveller's diarrhoea product, Travelan, complies with all US federal and state regulations for sale in the dietary and medical foods categories.
Anadis is currently in discussions with prospective US partners to begin sales of Travelan.
Travelan is based on antibodies from bovine colostrum, the 'first milk' of dairy cows which have been specifically immunised with antigens from pathogenic human bacteria and viruses, such as strains of E. coli bacteria that cause traveller's diarrhoea.
Travelan contains antibodies to 14 pathogenic strains of E. coli bacteria found in water supplies around the world.
The company is also seeking registration for Travelan in Canada, Singapore, Hong Kong, India, Thailand, Taiwan, Malaysia, the United Kingdom and Europe.
Light at night can increase heart disease risk
Being exposed to bright light at night can significantly increase your chances of developing...
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
